NIH U01 Grants — Research Project — Cooperative Agreement
Reviewed by Dr. Meng ZhaoLast reviewed June 9, 2026Data refreshed June 9, 2026Editorial standards
Investigator-led research with NIH staff substantial involvement
Funding
R01-like; varies
Duration
3–5 years
Eligibility
Investigators on NIH-led initiatives
Activity code
U01
What is the NIH U01 grant?
The U01 is a cooperative agreement — similar in scope and funding to an R01, but with substantial involvement from NIH program staff. NIH staff participate in steering committees, scientific decisions, and milestone definitions. U01s are common for clinical trials, network science, and consortia where NIH-driven coordination matters.
Recent U01 awards from NIH RePORTER
Examples of funded U01 projects across the last two fiscal years. The matching-award count comes from the full result set; funding totals, averages, rankings, and examples use the first 500 records returned by NIH RePORTER. Figures reflect a snapshot last refreshed on June 9, 2026.
Example U01 projects from the sample
Design, prediction, and prioritization of systematic perturbations of the human genome
3U01HG011967-05S1ANDREW ALLEN · DUKE UNIVERSITY, NC · $665,995 · awarded Jun 5, 2026 · NIHABSTRACT Noncoding genetic variation that alters gene regulation is of paramount importance for health, disease, and evolution. Diseases ranging in incidence from the most common to the most rare all have substantial risk associated with regulatory variation; and most of the genetic differences between closely related species are noncoding. Whole genome…
MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm
5U01CA200462-09ROBERT BAST · UNIVERSITY OF TX MD ANDERSON CAN CTR, TX · $1,112,552 · awarded Jun 5, 2026 · NIHABSTRACT: Advances in cytoreductive surgery and combination chemotherapy have improved 5-year survival in patients with epithelial ovarian cancer, but the rate of cure remains essentially unchanged over the last two decades. Computer models suggest that detection of ovarian cancer in early stage (I-II) could improve rates of cure by 10-30%. In two major…
Genetic and Microbiome Control of Addiction-like Behaviors in Mice
1U01DA064597-01Jason Bubier · JACKSON LABORATORY, ME · $805,077 · awarded Jun 3, 2026 · NIHPROJECT SUMMARY The research proposal addresses the urgent need for predictive biomarkers and pharmacological treatments for cocaine use disorder (CUD), a highly heritable disease affecting millions worldwide. Despite advances in understanding the genetic, cellular, and circuit mechanisms of CUD, effective treatments remain elusive. The proposal highlights…
A Multisite Study of Prenatal Alcohol Exposure: Effects of Inflammation and Endocrine Dysfunction in Adulthood
3U01AA026108-10S1Claire Coles · EMORY UNIVERSITY, GA · $292,150 · awarded Jun 1, 2026 · NIHAlthough the impact of prenatal alcohol exposure (PAE) on early development has been well established, the Developmental Origins of Health and Disease (DOHaD) hypothesis suggests there may be longer- term consequences that increase the risk for adult diseases or disorders. Previously, it has been difficult to isolate the effects of PAE from those associated…
Pathways for Regulatory Innovation and Strategic Modernization (PRISM)
1U01FD008948-01Amarnath Bhat · REAGAN-UDALL FOUNDATION/FOOD/DRUG/ADMIN, DC · $1,299,114 · awarded May 28, 2026 · FDAEffective engagement with the public is essential to expand the impact of the U.S. Food and Drug Administration, and for the efficient transfer of information and insights among the Agency, patients, academia, consumers, healthcare, and regulated industry. Through PRISM: Pathways for Regulatory Innovation and Strategic Modernization, the Reagan-Udall…
NAD Augmentation to Treat Diabetic Kidney Disease: A Randomized Controlled Trial
3U01AG076789-03S1SHALENDER BHASIN · BRIGHAM AND WOMEN'S HOSPITAL, MA · $314,717 · awarded May 26, 2026 · NIHSummary The primary aim of this study is to determine whether NAD augmentation by administration of nicotinamide mononucleotide (NMN) improves urinary albumin to creatinine ratio, a robust biomarker of diabetes kidney disease, and other biomarkers of kidney injury in adults with diabetes kidney disease. The trial is highly significant because it offers a…
Hybrid Intelligence for Trustable Diagnosis And Patient Management of Prostate Cancer (HIT-PIRADS)
5U01CA268808-04Ulas Bagci · NORTHWESTERN UNIVERSITY, IL · $375,760 · awarded May 19, 2026 · NIHProstate Cancer (PCa) is among the most common cancers in men worldwide, with an estimated 1.6M cases and 366K deaths annually [1]. The Prostate Imaging Reporting and Data System (PI-RADS) has become a standard tool for diagnosing PCa using multi-parametric MR images (mp-MRI). PI-RADS aims to standardize the way to classify the cancer grades. However,…
COMPASS: A comprehensive mobile precision approach for scalable solutions in mental health treatment
4U01MH136025-03Amy Bohnert · UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI · $10,264,092 · awarded May 19, 2026 · NIHMatching patients to the treatment most effective for them can accelerate recovery and meaningfully reduce the growing burden of mental health conditions. Key barriers to tailoring care are the lack of objective data that can predict treatment response and effective approaches to translate data to improved clinical outcomes. As a result, many patients…
Whole Body Effects of PAE Across the Life Span: Early Markers of & Clinical Interventions for Children and Adolescents in Ukraine
5U01AA014835-23CHRISTINA CHAMBERS · UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA · $580,092 · awarded May 19, 2026 · NIHProject Summary Numerous comorbidities have been identified as relatively common among children and adolescents with prenatal alcohol exposure (PAE) or fetal alcohol spectrum disorders (FASDs) including sleep disturbances, hypertension, abnormal eating behaviors, altered growth patterns, and comorbid depression and anxiety. In addition, emerging data…
Pediatric Acute Liver Failure Immune Response Network (PALF IRN): Treatment for Immune Mediated Pathophysiology (TRIUMPH)
5U01DK127995-05Estella Alonso · LURIE CHILDREN'S HOSPITAL OF CHICAGO, IL · $2,560,333 · awarded May 18, 2026 · NIHProject Summary Pediatric Acute Liver Failure (PALF) is a rare, devastating condition that affects an estimated 250 children per year in North America, causing death in approximately 15% and the need for liver transplantation (LT) in an additional 20-30%. In the majority of cases, a specific cause of the liver injury is never determined. Recent research…
Molecular Phenotyping of ARDS, Pneumonia, and Sepsis using Latent Class Analysis and Metagenomic Sequencing
5U01HL168415-04Carolyn Calfee · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA · $694,737 · awarded May 18, 2026 · NIHABSTRACT This application to RFA HL-23-001 proposes a California Clinical Center for participation in the Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis (APS) Consortium study. Our Clinical Center consists of 4 sites: University of California, San Francisco (UCSF; lead site); UCSF Fresno; Zuckerberg San Francisco General Hospital; and…
A Multisite Study of Prenatal Alcohol Exposure: Effects of Inflammation and Endocrine Dysfunction in Adulthood
5U01AA026108-10Claire Coles · EMORY UNIVERSITY, GA · $33,528 · awarded May 18, 2026 · NIHAlthough the impact of prenatal alcohol exposure (PAE) on early development has been well established, the Developmental Origins of Health and Disease (DOHaD) hypothesis suggests there may be longer- term consequences that increase the risk for adult diseases or disorders. Previously, it has been difficult to isolate the effects of PAE from those associated…
Funding institutes in the sample
| Institute | Awards | Funding |
|---|---|---|
| NIH | 447 | $468.6M |
| ALLCDC | 38 | $23.3M |
| FDA | 15 | $6.1M |
Most frequent institutions in the sample
- VANDERBILT UNIVERSITY MEDICAL CENTER — 17 awards
- JOHNS HOPKINS UNIVERSITY — 14 awards
- UNIVERSITY OF CALIFORNIA, SAN DIEGO — 13 awards
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI — 13 awards
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — 13 awards
- MASSACHUSETTS GENERAL HOSPITAL — 13 awards
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — 12 awards
- EMORY UNIVERSITY — 12 awards
Source: NIH RePORTER. Verify any award in the official record by searching its project number. See our data methodology for how this sample is built and its limitations.
Decision guide
Choose U01 when
Apply for U01 when an FOA you are responding to specifies the U01 mechanism, often because the program needs cross-site coordination.
Choose another mechanism when
For investigator-initiated work without NIH-led coordination, choose R01.
Who applies for U01
Investigators responding to U01 FOAs (which are typically more topic-specific than R01 PARs).
Compare nearby NIH grant mechanisms
Searchers often land on U01 while deciding between adjacent NIH activity codes. Compare scope, NIH staff involvement, budget scale, and applicant stage before choosing a funding opportunity.
Discrete, specified investigator-led research project
Multi-component centers with NIH program involvement
Large multi-component research with NIH involvement
For broad grant lookup, use the NIH grant search to find funded examples by activity code, PI, institution, and award year.
Search tips for U01
- U01 awards anchor NIH consortia like the HEAL Initiative, RECOVER (long COVID), and the Cancer Moonshot.
Search NIH grants by activity code
Find U01-funded PIs
U01 funding trends
U01 frequently asked questions
What is the difference between R01 and U01?
R01 is investigator-initiated with minimal NIH involvement once funded. U01 is a cooperative agreement with substantial NIH program staff involvement (steering committees, milestones).